초록 ▼

Disclosed is a pharmaceutical composition comprising (a) a bioerodible water insoluble polymer matrix comprising a polyester polymer, wherein the polymer matrix has a melting point of less than 60° C. and (b) an active agent dispersed within the polymer matrix, wherein the composition is formulated

Disclosed is a pharmaceutical composition comprising (a) a bioerodible water insoluble polymer matrix comprising a polyester polymer, wherein the polymer matrix has a melting point of less than 60° C. and (b) an active agent dispersed within the polymer matrix, wherein the composition is formulated to controllably release the active agent for a pre -determined period of time to a target site. Also disclosed are methods of treating a disease or condition with the disclosed compositions.

대표청구항 ▼

1. A pharmaceutical composition comprising: (a) a bioerodible water insoluble polymer matrix comprising a polyester polymer, wherein the polymer matrix has a melting point of less than 60° C. and wherein the polyester polymer has an average molecular weight of 400 to 4000 and wherein the polyester p

1. A pharmaceutical composition comprising: (a) a bioerodible water insoluble polymer matrix comprising a polyester polymer, wherein the polymer matrix has a melting point of less than 60° C. and wherein the polyester polymer has an average molecular weight of 400 to 4000 and wherein the polyester polymer is at least 80 wt % of the composition; and(b) an active agent dispersed within the polymer matrix;wherein the active agent is an ophthalmic drug and wherein the viscosity of the composition is from 100 to 2000 cps at 55° C. and wherein the composition is formulated to controllably release the active agent within a vitreous of an eye for a pre-determined period of time and wherein the composition is a liquid or paste that can be injected through a needle no larger than 22 gauge into the vitreous without requiring a physical change of the composition. 2. The pharmaceutical composition of claim 1, wherein the composition comprises a water miscible liquid incorporated in the matrix and wherein the concentration of the water miscible liquid is up to 50% (w/w). 3. The pharmaceutical composition of claim 2, wherein the water miscible organic liquid is miscible within the polymer matrix. 4. The pharmaceutical composition of claim 1, wherein the polymer matrix comprises a polymer selected from the group consisting of: poly(c-caprolactone)s; poly(ethylene glycol adipate)s; poly(propylene glycol adipate)s; poly(butylene glycol adipate)s; and blends and copolymers thereof. 5. The pharmaceutical composition of claim 4, wherein the polymer matrix comprises a poly(ε-caprolactone) polymer. 6. The pharmaceutical composition of claim 1, wherein the polymer matrix comprises a polyester polymer selected from the group consisting of: whereinR1, R2 and R3 are independently selected from the group consisting of alkyl and alkoxyl diols, triols and tetraols of 2 to 8 carbon atoms;w, w1 are independently an integer from 4 to 12;W2, w3 are independently an integer from 1 to 12;W4, w5, w6, w7, w8, w9 and w10 are independently an integer from 0 to 12;n is an integer from 4 to 9; andm is an integer from 2 to 8. 7. The pharmaceutical composition of claim 6, wherein R1, R2 and R3 are independently selected from the group consisting of butanediol, hexanediol, neopentyl glycol, diethylene glycol, trimethylol propane and pentaerythritol. 8. The pharmaceutical composition of claim 1, wherein the polymer matrix comprises a polymer having the formula (C6H10O2)x.(C5H8O4) where x is such that the polymer has an average molecular weight of about 1000. 9. The pharmaceutical composition of claim 1, wherein the ophthalmic drug has anti-infective or anti-allergic properties. 10. The pharmaceutical composition of claim 1, wherein the ophthalmic drug is an ocular hypotensive drug selected from the group consisting of carbonic anhydrase inhibitors; beta-blockers; prostaglandins; bradykinin agonists; rho-kinase inhibitors; C-type natriuretic peptide receptor agonists, and guanylate cyclase activators. 11. A kit comprising the composition of claim 1 and a syringe. 12. The pharmaceutical composition of claim 1, wherein the polyester polymer is at least 85 wt % of the composition. 13. The pharmaceutical composition of claim 6, wherein the polyester polymer is at least 85 wt % of the composition. 14. The pharmaceutical composition of claim 1 wherein the ophthalmic drug is for treatment of age-related macular degeneration. 15. The pharmaceutical composition of claim 13 wherein the therapeutic agent is an ophthalmic drug for treatment of age-related macular degeneration.